Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331395 | 0.87 | CACNA1I (0.60) | CACNA1IKCNH2HTR4CACNA1GCACNA1H | |
| SCHEMBL6328599 | 0.85 | CACNA1I (0.47) | CACNA1IKCNH2HTR4 | |
| SCHEMBL6328578 | 0.83 | CACNA1I (0.49) | CACNA1IKCNH2HTR4CACNA1GCACNA1H | |
| SCHEMBL6331443 | 0.82 | HTR4 (0.48) | CACNA1IKCNH2HTR4 | |
| SCHEMBL6334928 | 0.81 | CACNA1I (0.49) | CACNA1IKCNH2HTR4 | |
| SCHEMBL6331058 | 0.81 | GSK3B (0.47) | CACNA1IKCNH2HTR4 | |
| SCHEMBL7254884 | 0.81 | HTR4 (0.46) | CACNA1IKCNH2HTR4 | |
| SCHEMBL6330758 | 0.80 | HTR4 (0.45) | CACNA1IKCNH2HTR4 | |
| SCHEMBL6335673 | 0.80 | HTR4 (0.49) | CACNA1IKCNH2HTR4 | |
| SCHEMBL14258189 | 0.79 | NR4A2 (0.53) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | claimed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | claimed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| WO-2003057688-A2 | OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-07-17 | — | — | WO | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | CACNA1I 1644/4885KCNH2 1888/4885HTR4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.